APX-3330

N/A

Report date: 2025/06/28 20:00:07
NMEFirst In Class

Base Information

Drug NameAPX-3330
Drug Alias NameAPX-3330E-3330
ClassificationSmall molecules
Mechanisms of ActionDNA-(apurinic or apyrimidinic site) lyase inhibitorsAngiogenesis inhibitors
TargetsDNA-(apurinic or apyrimidinic site) lyase
Therapy Area/IndicationsDiabetic macular oedemaSolid tumoursDiabetic Retinopathy +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesApexian Pharmaceuticals IncOpus Genetics Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaSolid tumoursDiabetic Retinopathy +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A